系统性高血压与肺动脉高压患者生存的关联
结果显示,合并高血压者死亡风险降低26%(HR 0.74,95%CI 0.68-0.79),且生存获益与基线收缩压升高(80-180 mmHg)正相关,在随访中收缩压下降和心率升高则与死亡风险增加相关。
要点
- 合并系统性高血压的肺动脉高压患者死亡风险显著降低(HR 0.74)。
- 基线收缩压80-180 mmHg范围内升高与生存改善正相关。
- 随访中收缩压下降和心率升高提示死亡风险增加。
核心结论
- 在肺动脉高压患者中,较高的基线收缩压和合并系统性高血压与改善的生存独立相关。
- 随访期间收缩压下降和较高心率与死亡风险增加显著相关。
研究设计与样本
- 生存分析采用多变量Cox比例风险模型调整关键混杂因素,并进行敏感性分析和英国独立外部验证。
主要发现
- 合并高血压患者较无高血压者死亡风险降低26%(HR 0.74;95%CI 0.68-0.79)。
- 生存获益与收缩压升高(80-180 mmHg)正相关,在各PH分组和年龄组中一致,且独立于降压药和PH特异性药物。
- 心率升高与较高死亡率相关;收缩压升高与心脏指数和三尖瓣环收缩期位移改善相关。
- 随访中收缩压下降和心率升高与较高死亡率相关;英国外部验证队列证实上述发现。
临床怎么用
- 在评估肺动脉高压患者预后时,可将基线收缩压水平和是否合并系统性高血压作为预后参考因素。
- 随访中监测收缩压下降和心率升高可能有助于识别死亡风险增加的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Pulmonary hypertension (PH), a progressive and life-threatening condition with rising prevalence among older adults, frequently coexists with systemic hypertension, the prognostic impact of which is poorly understood. OBJECTIVE: To evaluate the association between systemic hypertension and survival in patients with PH. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study analyzed data from the Pulmonary Vascular Research Institute GoDeep meta-registry, integrating global retrospective and prospective PH cohorts (n = 3238 in Europe, n = 3014 in North America, n = 96 in Africa, n = 802 in Asia, and n = 851 in Oceania). Survival was assessed using multivariable Cox proportional hazards models and adjusted for key confounders, with sensitivity analyses to validate robustness. Independent external validation was performed in a cohort in the UK. A total of 12 771 patients with incident PH (median [IQR] age, 65 [53-73] years; 7372 [58%] female) were diagnosed via right heart catheterization and comprehensive clinical data, encompassing PH groups 1-5 and all age categories. The study spans diagnosis decades from 1980 to 2020. Data were analyzed from February 2025 until September 2026. EXPOSURES: Center-reported diagnosis of systemic hypertension, baseline systolic systemic arterial pressure (sSAP), and heart rate as well as longitudinal sSAP and heart rate trajectories. MAIN OUTCOMES AND MEASURES: All-cause mortality, adjusted for confounding variables, including age, PH group, antihypertensive and PH-specific medications, and cardiac index. RESULTS: Higher baseline sSAP and preexisting systemic hypertension were independently associated with improved survival. Patients with hypertension exhibited a 26% reduced mortality hazard (hazard ratio [HR], 0.74; 95% CI, 0.68-0.79) compared to their counterparts without hypertension. Survival benefits correlated positively with increasing sSAP (80-180 mm Hg), remained consistent across PH groups and age groups, and were independent of antihypertensive and PH-specific medications. Elevated heart rate was associated with higher mortality. sSAP increments correlated with improved cardiac index and tricuspid annular plane systolic excursion. Decreased sSAP and higher heart rate during follow-up correlated with higher mortality. External validation in a separate UK cohort confirmed these findings. CONCLUSION AND RELEVANCE: In this global PH cohort, higher sSAP was associated with enhanced survival, while a higher baseline heart rate and declining systemic blood pressure during follow-up were significantly associated with increased mortality risk.
引用
- Yogeswaran A, Berger M, De Bie E, et al. Systemic Hypertension and Survival in Pulmonary Hypertension. JAMA Cardiol. 2026. PMID: 42961442. doi:10.1001/jamacardio.2026.4834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。